Penpulimab vs Tislelizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Penpulimab

Marketed by Akeso and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03866993 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.

Reported efficacy

Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)

Result source: NCT03866993

Tislelizumab

Marketed by BeOne Medicines and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03358875 · Phase 3 · completed

The 805-participant trial was randomized and actively controlled with docetaxel, and its co-primary clinical endpoint of overall survival was met in both the full population and the PD-L1-positive subgroup. However, treatment assignment was not blinded, so despite the large sample and statistically significant survival results, the evidence is rated moderate rather than strong.

Next expected readout: November 2026 · NCT06704620 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPenpulimabTislelizumab
PFS, median8.6 vs 4.2a+4.4 vs placeboNCT038669937.6 vs 5.5vs Paclitaxel + Carboplatinn 120NCT03594747
5 other results
OS, median—Not posted · NCT0386699326.1 vs 19.4vs Paclitaxel + Carboplatinn 120NCT03594747
1 other result
ORR—Not posted · NCT0386699374.2% vs 47.9%vs Paclitaxel + Carboplatinn 120NCT03594747
3 other results
  • 73.9% vs 47.9% n 119 · Phase 3 · secondary NCT03594747
  • 70% vs 49.6% n 120 · Phase 3 · secondary NCT03594747
  • 78.2% vs 49.6% n 119 · Phase 3 · secondary NCT03594747
Duration of response, median—Not posted · NCT038669938.4 vs 4.3vs Paclitaxel + Carboplatinn 89NCT03594747
3 other results

PFS, median

Penpulimab
8.6 vs 4.2a+4.4 vs placeboNCT03866993
Tislelizumab
7.6 vs 5.5vs Paclitaxel + Carboplatinn 120NCT03594747
5 other results

OS, median

Penpulimab
—Not posted · NCT03866993
Tislelizumab
26.1 vs 19.4vs Paclitaxel + Carboplatinn 120NCT03594747
1 other result

ORR

Penpulimab
—Not posted · NCT03866993
Tislelizumab
74.2% vs 47.9%vs Paclitaxel + Carboplatinn 120NCT03594747
3 other results
  • 73.9% vs 47.9% n 119 · Phase 3 · secondary NCT03594747
  • 70% vs 49.6% n 120 · Phase 3 · secondary NCT03594747
  • 78.2% vs 49.6% n 119 · Phase 3 · secondary NCT03594747

Duration of response, median

Penpulimab
—Not posted · NCT03866993
Tislelizumab
8.4 vs 4.3vs Paclitaxel + Carboplatinn 89NCT03594747
3 other results
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Penpulimab: 0 of 4 rows · Tislelizumab: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPenpulimabTislelizumab
Dropout rate—
n/a: no completion milestoneTislelizumab + Nab-paclitaxel + Caa
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
n/a: no completion milestoneTislelizumab + Paclitaxel + Carbop
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Discontinued due to AEs—
—Tislelizumab + Nab-paclitaxel + Caa
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
—Tislelizumab + Paclitaxel + Carbop
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Serious AEs—
46.6%Tislelizumab + Nab-paclitaxel + Caa
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
46.7%Tislelizumab + Paclitaxel + Carbop
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Most frequent reported AEs—
a
anaemia 94.1%
alopecia 69.5%
neutrophil count decreased 61.9%
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
anaemia 89.2%
alopecia 65%
neutrophil count decreased 65%
NCT03594747 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tislelizumab

Overall Survival 26.1 vs 19.4 Paclitaxel + Carboplatin months
time to event · months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
23.3 vs 19.4 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
ORR 74.2% (n=120) vs 47.9% (n=121) Paclitaxel + Carboplatin
responder rate · % of participants
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
73.9% (n=119) vs 47.9% (n=121) Paclitaxel + Carboplatin
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
70% (n=120) vs 49.6% (n=121) Paclitaxel + Carboplatin
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
78.2% (n=119) vs 49.6% (n=121) Paclitaxel + Carboplatin
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Duration of Response 8.4 vs 4.3 Paclitaxel + Carboplatin months
time to event · months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
8.6 vs 4.3 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
10.6 vs 4.8 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
8.8 vs 4.8 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-LC13 Chest Pain 0.4 score @ 15wk
absolute change · score
No placebo or comparator arm
Chest pain
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-0.4 score @ 15wk
Chest pain
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ LC13 Cough -7 score @ 15wk
absolute change · score
No placebo or comparator arm
Coughing
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-0.4 score @ 15wk
Coughing
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 GHS 2.4 score @ 15wk
absolute change · score
No placebo or comparator arm
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
3.3 score @ 15wk
NCT03594747 · Phase 3 · registry result, not featured evidence · combination

Nasopharyngeal Carcinoma

Shared mechanism: PD-1 · full Nasopharyngeal Carcinoma pipeline

Penpulimab

Marketed by Akeso and partners

Approved in Nasopharyngeal Carcinomamonoclonal antibody
Reliable signal

NCT04974398 · Phase 3 · active, not recruiting

Patients were randomly assigned to penpulimab or a matching placebo with patients, doctors and assessors all blinded, and the trial met its primary endpoint, progression-free survival judged by blinded central review. A power calculation was reported, and 291 patients were randomized against a planned 278.

No aligned efficacy figure on record for this race.

Tislelizumab

Marketed by BeOne Medicines and partners

Phase 3 in Nasopharyngeal Carcinomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06177301 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Nasopharyngeal Carcinoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Penpulimab: no structured comparison results are available for Nasopharyngeal Carcinoma.

Tislelizumab: registry results are on file for Nasopharyngeal Carcinoma, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Penpulimab's landscape · Tislelizumab's landscape